Cancer Therapy Global Market Report 2025

The cancer therapy market size has grown rapidly in recent years. It will grow from $190.44 billion in 2024 to $210.44 billion in 2025 at a compound annual growth rate (CAGR) of 10.5%. The growth during the historic period can be attributed to the rising global prevalence of cancer, increasing adoption of chemotherapy treatments, heightened awareness of early cancer diagnosis, greater availability of oncology specialists, and expanded access to hospital-based treatment services.

The cancer therapy market size is expected to see rapid growth in the next few years. It will grow to $310.85 billion in 2029 at a compound annual growth rate (CAGR) of 10.2%. The growth projected for the forecast period is driven by increasing demand for personalized cancer therapies, a stronger focus on outpatient cancer care, rising adoption of immunotherapy, improved healthcare access in emerging economies, and a growing incidence of lifestyle-related cancers. Key trends during this period include technological advancements in cancer diagnostics, innovations in targeted drug delivery, increased investment in biologics research and development, the development of AI-based treatment planning, and innovations in minimally invasive cancer surgeries.

The rising prevalence of cancer is expected to drive growth in the cancer therapy market moving forward. Cancer is a group of diseases characterized by the uncontrolled growth and spread of abnormal cells in the body. The increase in cancer cases is mainly due to greater exposure to environmental carcinogens such as pollution and tobacco smoke. Cancer therapy is vital in managing this rising prevalence by treating existing cases, enhancing survival rates, and slowing disease progression. For example, in February 2024, the World Health Organization (WHO), a Switzerland-based intergovernmental organization, projected that global cancer incidence will exceed 35 million new cases by 2050, marking a 77% rise from the estimated 20 million cases reported in 2022. Thus, the growing prevalence of cancer is fueling the expansion of the cancer therapy market.

Leading companies in the cancer therapy market are concentrating on developing innovative treatments, such as immuno-oncology drugs, which enhance treatment effectiveness by leveraging the body’s immune system to identify and destroy cancer cells. Immuno-oncology drugs represent a class of cancer therapies that stimulate or boost the immune system’s ability to more effectively target and attack cancer cells. For example, in December 2024, Dr. Reddy’s Laboratories Ltd., an India-based pharmaceutical firm, launched Toripalimab, the first and only immuno-oncology drug approved for treating nasopharyngeal cancer in India. This introduction offers a new, targeted treatment option for patients with this rare and aggressive cancer, potentially improving outcomes through advanced immune system activation. The availability of Toripalimab in India highlights Dr. Reddy’s dedication to increasing access to advanced cancer therapies in underserved regions.

In December 2023, Pfizer Inc., a pharmaceutical company based in the US, acquired Seagen Inc. for $43 billion. Through this acquisition, Pfizer seeks to enhance its oncology portfolio by incorporating Seagen’s advanced antibody-drug conjugate (ADC) technology to deliver more targeted cancer treatments. Seagen Inc., also based in the US, specializes in developing ADCs that accurately target cancer cells while reducing damage to healthy tissue.

Major players in the cancer therapy market are Pfizer Inc., Johnson & Johnson, F. Hoffmann-La Roche Ltd, Merck & Co. Inc., Bayer AG, Bristol-Myers Squibb Company, AstraZeneca PLC, Novartis International AG, GlaxoSmithKline PLC, Elekta AB, Exelixis Inc., Accuray Incorporated, Akeso Inc., Nanobiotix S.A., SOTIO Biotech a.s., AdvanCell Isotopes Pty Ltd, Axcynsis Therapeutics Pte Ltd, Clarity Pharmaceuticals Ltd, Affimed N.V., and Aptadel Therapeutics S.L.

North America was the largest region in the cancer therapy market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in cancer therapy report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the cancer therapy market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Cancer therapy refers to treatments aimed at eliminating or controlling cancer cells within the body. It encompasses several methods, including surgery, chemotherapy, radiation therapy, immunotherapy, and targeted therapy. The selection of treatment depends on the cancer’s type, stage, location, and the patient’s overall health.

The primary types of cancer therapy include chemotherapy, targeted therapy, immunotherapy, radiotherapy, and others. Chemotherapy involves using potent drugs to kill or inhibit the growth of rapidly dividing cancer cells. It is applied to various cancers such as blood cancer, breast cancer, prostate cancer, gastrointestinal cancer, gynecologic cancer, respiratory or lung cancer, and more. This treatment is utilized by various end users, including hospitals, specialty clinics, and cancer and radiation therapy centers.

The cancer therapy market research report is one of a series of new reports that provides cancer therapy market statistics, including the cancer therapy industry global market size, regional shares, competitors with the cancer therapy market share, detailed cancer therapy market segments, market trends, and opportunities, and any further data you may need to thrive in the cancer therapy industry. This cancer therapy market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The cancer therapy market includes revenues earned by entities by providing services such as hormone therapy, stem cell transplant, cryoablation, and photodynamic therapy. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.